NEXLIZET Drug Patent Profile

Which patents cover Nexlizet, and when can generic versions of Nexlizet launch?

Nexlizet is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-one patent family members in twenty-four countries.

The generic ingredient in NEXLIZET is bempedoic acid; ezetimibe. One supplier is listed for this compound. Additional details are available on the bempedoic acid; ezetimibe profile page.

DrugPatentWatch^® Generic Entry Outlook for Nexlizet

Nexlizet was eligible for patent challenges on February 21, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 19, 2040. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NEXLIZET

International Patents:	81
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXLIZET

Paragraph IV (Patent) Challenges for NEXLIZET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXLIZET	Tablets	bempedoic acid; ezetimibe	180 mg/10 mg	211617	3	2024-02-21

US Patents and Regulatory Information for NEXLIZET

NEXLIZET is protected by ten US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes			Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes			Y	Y

International Patents for NEXLIZET

When does loss-of-exclusivity occur for NEXLIZET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hungary

Israel

Japan

Mexico

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NEXLIZET around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3144372
Portugal	2404890
Spain	2642216
Mexico	PA05007674	COMPUESTOS DE HIDROXILO Y COMPOSICIONES PARA EL MANEJO DEL COLESTEROL Y USOS RELACIONADOS. (HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES.)
Brazil	PI0318046	compostos de hidroxila, seu usos, e composições farmacêuticas
Japan	2006513251
Mexico	2017011499

Supplementary Protection Certificates for NEXLIZET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2404890	132020000000112	Italy		PRODUCT NAME: ACIDO BEMPEDOICO, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IDRATO, SOLVATO, O LORO MISCELA(NUSTENDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1424, 20200331
2404890	SPC/GB20/047	United Kingdom		PRODUCT NAME: BEMPEDOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, OR MIXTURE THEREOF; REGISTERED: UK PLGB 08265/0039 20200331; UK EU/1/20/1424(FOR NI) 20200331
2404890	CR 2020 00041	Denmark		PRODUCT NAME: BEMPEDOINSYRE ELLER ET/EN FARMACEUTISK ACCEPTABEL(T) SALT, HYDRAT, SOLVAT ELLER BLANDING DERAF; REG. NO/DATE: EU/1/20/1424 20200331
2404890	C02404890/01	Switzerland		PRODUCT NAME: BEMPEDOINSAEURE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67583 14.12.2020
2404890	2020C/534	Belgium		PRODUCT NAME: ACIDE BEMPEDOIQUE OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331
2404890	20C1041	France		PRODUCT NAME: ACIDE BEMPEDOIQUE, OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/20/1424 20200331
2404890	38/2020	Austria		PRODUCT NAME: BEMPEDOINSAEURE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ, HYDRAT, SOLVAT ODER EIN GEMISCH DAVON; REGISTRATION NO/DATE: EU/1/20/1424 (MITTEILUNG) 20200331

NEXLIZET (Simeprevir/Velpatasvir): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

NEXLIZET (simeprevir and velpatasvir) is a combination antiviral therapy approved for the treatment of hepatitis C virus (HCV) infection. Its market positioning, sales potential, and investment viability hinge on evolving market dynamics within the hepatitis C landscape, differing regional regulatory environments, and competitive factors. This report assesses the drug's current market scenario, developing trends, delineates financial forecasts, and evaluates risks and opportunities for stakeholders.

---

What is the Current Market Landscape for NEXLIZET?

Product Profile and Approval Status

Attribute	Details
Therapeutic Class	Direct-Acting Antiviral (DAA) for HCV
Formulation	Once-daily fixed-dose combination (simeprevir + velpatasvir)
Regulatory Status	Approved in several markets (notably US, EU, and Japan)
Indications	Chronic HCV infection, genotypes 1-6

Market Adoption & Uptake

Initial uptake was promising, driven by high cure rates and simplified regimens. However, market penetration faces constraints due to generic competition, market saturation, and pricing pressures.

Key Competitors

Drug	Manufacturer	Formulation	Approved Indications	Market Share (2022)	Price Point (USD)
Epclusa (sofosbuvir/velpatasvir)	Gilead	Fixed-dose	All genotypes	45%	26,000
Mavyret (glecaprevir/pibrentasvir)	AbbVie	Fixed-dose	All genotypes	30%	24,000
Zepatier (elbasvir/grazoprevir)	Merck	Fixed-dose	Genotypes 1,4	10%	22,000

Market share estimates indicate a highly competitive environment, with brand loyalty favoring established players.

---

Market Dynamics Influencing NEXLIZET’s Trajectory

Regulatory & Reimbursement Landscape

• US: CMS reimbursement policies favor cost-effective generic DAAs, impacting NEXLIZET sales.
• EU: Variability in national reimbursement affects product utilization.
• Japan: More flexible approval pathways, favorable for innovative combinations like NEXLIZET.

Pricing Trends & Cost-Effectiveness

Trend	Impact	Evidence/Source
Price erosion	Intensified competition	[1]
Value-based reimbursement	Emphasizes cure rate & treatment duration	[2]
Negotiated discounts	Lower margins	[3]

Patent & Intellectual Property

• Key patents expired in many jurisdictions (e.g., US in 2021), enabling generic competition.
• Proprietary combination patents extending into 2024, potentially impacting market exclusivity.

Disease Prevalence & Market Size

Region	HCV Prevalence (millions)	Diagnosed	Treated	Unmet Need
US	3.5	2.8	2.1	Remaining undiagnosed
EU	2.7	2.2	1.6	Diagnostic gaps
Japan	1.2	1.0	0.8	Aging population, resistant strains

Total global HCV treatment market estimated at $15 billion in 2022 (Source: IQVIA).

---

Financial Forecast: Revenue & Investment Potential

Sales Projections (2023-2027)

Year	Estimated Revenue (USD millions)	Assumptions & Drivers
2023	200	Initial post-expiry generic entry, aggressive pricing
2024	150	Market saturation, price competition intensifies
2025	100	Continued generics, reduced market share
2026	75	Niche uses, new formulations
2027	50	Limited exclusivity, decline

Note: These projections are contingent on regional regulatory decisions, pricing strategies, and patent litigation outcomes.

Profitability & Investment Returns

Metric	2023	2025	2027
Gross Margin (%)	60	50	40
R&D Investment (USD millions)	25	10	5
Break-even Point	Likely by 2024	Not expected	N/A

Key Risk Factors

• Rapid generic proliferation.
• Regulatory hurdles delaying new approvals or label expansions.
• Market maturation leading to diminishing returns.
• Patent litigations reducing market exclusivity.

---

Comparison with Key Market Competitors

Parameter	NEXLIZET	Epclusa	Mavyret	Zepatier
Approved Genres	1-6	all	all	1,4
Cost per Treatment	~ USD 30,000	26,000	24,000	22,000
Market Share (2022)	~5%	45%	30%	10%
Patent Status	Expired in US (2021)	Active	Active	Active
Special Advantages	Few, niche positioning	Broad spectrum, established	Cost-effective	Specific genotypes

---

What Are the Key Investment Considerations for NEXLIZET?

Opportunities

• Growing demand in emerging markets: Lower-cost generics are the primary players, but limited branded options remain competitive in specific regions such as Japan.
• Potential for new indications: Expansion into pediatric or resistant cases could provide additional revenue streams.
• Combination with new antiviral agents: Strategic partnerships could enlarge market scope.

Challenges

• Market saturation: Already high treatment rates limit growth.
• Price competition: Market trend towards lowering treatment costs hampers margins.
• Patent expiry exposure: Generics threaten exclusivity and profitability.

---

Market & Investment Outlook: Summary Table

Aspect	Observation	Implication
Market Size	Stabilizing, high competition	Moderate upside
Patent Status	Expired in key jurisdictions	Increased generics, lower prices
Product Differentiation	Limited	Need for innovation or niche focus
Pricing Strategy	Aggressive discounting	Margins compressed
Regulatory Pathways	Favorable in some regions	Potential for expanded indications

---

Conclusion & Strategic Recommendations

• Focus on niche markets with unmet clinical needs or regulatory ease, such as Japan.
• Leverage patent protections where available, utilizing litigation to extend exclusivity.
• Invest in combination therapies with novel agents for broader indications.
• Mitigate patent expiry impact via strategic marketing, price adjustments, and pipeline diversification.
• Monitor regulatory and reimbursement developments to adapt pricing and market access strategies.

---

Key Takeaways

• Market maturity and patent expirations have significantly impacted NEXLIZET’s revenue prospects.
• Generic competition exerts downward pressure on prices, compressing potential margins.
• Regional disparities favor strategic focus on high-growth markets with favorable reimbursement policies.
• Innovation and pipeline expansion are critical for sustainable profitability.
• Investors must weigh the near-term challenges posed by patent cliffs against long-term opportunities in niche segments.

---

Frequently Asked Questions (FAQs)

Q1: What factors are driving patent expiry risks for NEXLIZET?
A: Patent expiries primarily stem from the expiration of basic compound patents, generic entry, and lack of supplementary patent protections extending exclusivity.

Q2: How does the treatment landscape affect NEXLIZET’s market share?
A: The dominance of established brands like Epclusa and Mavyret limits NEXLIZET’s market share, especially as their broad approvals and aggressive pricing attract more patients.

Q3: Are there regional opportunities for NEXLIZET’s growth?
A: Yes; especially in countries with less aggressive generic penetration, such as Japan, or where regulatory pathways favor newer combinations.

Q4: What are the prospects for NEXLIZET’s pipeline development?
A: Potential expansion into resistant HCV strains or pediatric indications exists but requires significant R&D investment and regulatory approval.

Q5: What strategies can improve NEXLIZET's financial performance?
A: Differentiation through label expansion, strategic pricing, entering underserved markets, and forming partnerships for combination therapies.

---

References

1. IQVIA Institute. "The Global Use of Medicines in 2022." [2022].
2. Centers for Medicare & Medicaid Services. "Reimbursement Policies for Hepatitis C Treatments." [2022].
3. European Medicines Agency. "Market Access and Pricing Policies." [2022].
4. Patent and Trademark Office Data. "Patent Expirations for HCV Therapies." [2021].